PRINCETON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Soligenix, Inc., (Soligenix or the Company) , formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that its Chief Financial Officer Evan Myrianthopoulos will present a company overview highlighting recent developments at the BIO Investor Forum.
The Soligenix presentation will be webcast live and archived for later replay. To access the webcast, please visit the company’s investor page at http://www.soligenix.com/invest_sec.shtml. The replay will be available 24 hours after the live presentation and will be accessible for 30 days.
The 8th Annual BIO Investor Forum is an international conference featuring late-stage private and emerging public companies. This year’s BIO Investor Forum will include healthcare venture and private equity investors, buy-side investors and research analysts, as well as business development executives from leading global pharmaceutical and mature biotechnology companies.
Soligenix, Inc. (Soligenix), formerly known as DOR BioPharma, Inc., is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix’s lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec(R) is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD and an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Soligenix also expects to begin an NIH-supported Phase 1/2 clinical trial of SGX201 in radiation enteritis in the second half of 2009. Additionally, Soligenix has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.
For further information regarding Soligenix, Inc., please visit the Company’s website at www.soligenix.com.
Soligenix, Inc.
